

# Intrauterine insemination for unexplained or mild male subfertility

Gepubliceerd: 18-12-2015 Laatst bijgewerkt: 18-08-2022

We hypothesize that 6 months of expectant management does not result in decreased ongoing pregnancy rates as 6 months of treatment with IUI-OH.

**Ethische beoordeling** Positief advies

**Status** Werving gestopt

**Type aandoening** -

**Onderzoekstype** Interventie onderzoek

## Samenvatting

### ID

NL-OMON29303

### Bron

Nationaal Trial Register

### Verkorte titel

exIUI

### Aandoening

Unexplained subfertility, onverklaarde subfertiliteit, intrauterine insemination, intra uteriene inseminatie, IUI, expectant management, expectatief

### Ondersteuning

**Primaire sponsor:** AMC

**Overige ondersteuning:** ZonMW

### Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

The primary outcome is ongoing pregnancy leading to a live birth occurring within 6 months after randomization. Live birth is defined as the birth of a live baby at 24 or more weeks of

gestation.

## Toelichting onderzoek

### Achtergrond van het onderzoek

**BACKGROUND:** Of the 20,000 couples who yearly seek fertility treatment, more than 50% are diagnosed with unexplained or mild male factor subfertility. In The Netherlands, the first line treatment for these women is intrauterine insemination with ovarian hyperstimulation (IUI-OH) if the probability of a natural conception within the following year is lower than 30% according

to the validated model of Hunault. An estimated 28,500 cycles are conducted every year in the Netherlands, costing approximately 20 million euros, without any evidence that IUI-OH increases live birth rate compared to expectant management. Besides the costs, IUI-OH bears a risk of multiple pregnancies. Women with a multiple pregnancy have an increased risk of premature birth, with associated neonatal mortality and morbidity.

**THE PRIMARY OBJECTIVE:** To evaluate whether expectant management for 6 months does not lead to a decrease in ongoing pregnancy rate leading to a live birth compared to 6 months IUI-OH.

**HYPOTHESIS:** We hypothesize that 6 months of expectant management does not result in decreased ongoing pregnancy rates compared to 6 months of treatment with IUI-OH.

**STUDY DESIGN:** randomized multicentre, non-inferiority trial with cost-effectiveness analysis.

**STUDY POPULATION** Couples diagnosed with unexplained or mild male subfertility according to the Dutch guideline and an unfavourable prognosis for natural conception.

**INTERVENTION:** 6 months expectant management.

**STANDARD INTERVENTION TO BE COMPARED:** 6 months IUI-OH .

**OUTCOME MEASURES:** Ongoing pregnancies leading to a live birth conceived within 6 months after randomisation

**SAMPLE SIZE:** We expect a 30% live birth rate after 6 months IUI-COH. To evaluate whether 6 months expectant management does not result in a decrease of an ongoing pregnancy rate of 7%, we need 982 patients. (power 80%, alpha error 0.05). Anticipating 10% lost to follow up, we need to randomise 1,091 women.

### Doele van het onderzoek

We hypothesize that 6 months of expectant management does not result in decreased ongoing pregnancy rates as 6 months of treatment with IUI-OH.

## **Onderzoeksopzet**

6 months

## **Onderzoeksproduct en/of interventie**

Expectant management (experimental arm) vs intra uterine insemination with ovarian hyperstimulation (control arm)

## **Contactpersonen**

### **Publiek**

Centrum voor Voortplantingsgeneeskunde Q3-119 Academisch Medisch Centrum  
F. Mol  
Amsterdam  
The Netherlands  
020 5663557

### **Wetenschappelijk**

Centrum voor Voortplantingsgeneeskunde Q3-119 Academisch Medisch Centrum  
F. Mol  
Amsterdam  
The Netherlands  
020 5663557

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

12 months unprotected intercourse without conception, female age between 18 and 42 years, a regular ovulatory cycle and at least one patent fallopian tube. The male partner has no or a mild impairment of semen quality with a total motile sperm count (TMSC or VCM) above 3 million. Obtained written informed consent. A 12-month prognosis for natural conception (calculated according to the model of Hunault) of 30% or less, or a 12-month prognosis of more than 30% and returning after 6 months of expectant management without conception.

## **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

IUI-OH with sperm donation, couples with a medical contra indication for pregnancy, couples with previous ART in the current treatment episode

## **Onderzoeksopzet**

### **Opzet**

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Open / niet geblindeerd
Controle:	Geneesmiddel

### **Deelname**

Nederland	
Status:	Werving gestopt
(Verwachte) startdatum:	01-10-2016
Aantal proefpersonen:	1091
Type:	Werkelijke startdatum

## **Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)**

**Wordt de data na het onderzoek gedeeld:** Ja

## **Ethische beoordeling**

Positief advies	
Datum:	18-12-2015
Soort:	Eerste indiening

## **Registraties**

## **Opgevolgd door onderstaande (mogelijk meer actuele) registratie**

Geen registraties gevonden.

## **Andere (mogelijk minder actuele) registraties in dit register**

Geen registraties gevonden.

## **In overige registers**

<b>Register</b>	<b>ID</b>
NTR-new	NL5455
NTR-old	NTR5599
Ander register	AMC : 80-83700-98-16505

## **Resultaten**